Skip to main content

Table 1 Patient characteristics before venovenous extracorporeal membrane oxygenation

From: The impacts of baseline ventilator parameters on hospital mortality in acute respiratory distress syndrome treated with venovenous extracorporeal membrane oxygenation: a retrospective cohort study

 

All

(n = 106)

Survivor

(n = 50)

Non-survivor

(n = 56)

P

Age (year)

53 ± 15

51 ± 15

55 ± 15

0.11

Male

71 (67)

35 (70)

36 (64)

0.53

Predicted body weighta (kg)

55 ± 14

55 ± 16

55 ± 11

0.89

Hospital day before ECMO

6 (1–14)

2(1–9)

11(4–20)

<0.001*

Mechanical ventilation before ECMO (day)

3 (1–9)

1(0–4)

6(1–12)

<0.001*

Cause of ARDS

 Viral pneumonia

24 (21)

11 (22)

13 (23)

0.88

 Bacterial pneumonia

38 (37)

16 (32)

22 (39)

0.54

Fungal pneumonia

3 (3)

0

3 (6)

0.25

 Aspiration pneumonitis

3 (3)

3 (6)

0

0.10

 Other acute respiratory diagnoses

38 (36)

20 (40)

18 (32)

0.40

Acute associated infection

24 (21)

11 (22)

13 (23)

0.88

Immunocompromised statusb

37 (35)

11 (22)

26 (46)

0.008*

Renal failure requiring dialysis

28 (26)

13 (26)

15 (27)

0.93

Creatinine (mg/dL)

1.6 (0.8–3.4)

2.8 ± 3.3

2.3 ± 2.3

0.36

Total bilirubin (mg/dL)

1.5 ± 2.5

1.1 ± b1.2

1.9 ± 3.2

0.14

Platelet count (109/L)

137 (83–218)

172 (113–237)

106 (60–161)

0.002*

Hemoglobin (g)

10 (9–12)

11 (9–12)

10 (9–11)

0.08

SOFA score

10 (8–11)

9 (7–10)

10 (9–12)

0.002*

RESP score

2 ± 3

2 ± 3

1 ± 3

0.05*

  1. Data were presented as mean ± standard deviation in normal-distributed numerical variables, median (interquartile range) in numerical variables not normal-distributed, and n (%) in categorical variables. ECMO Extracorporeal membrane oxygenation, SOFA sequential organ failure assessment, RESP score Respiratory extracorporeal membrane oxygenation survival prediction score, ARDS Acute respiratory distress syndrome. a Ideal body weight is calculated by the ARDSnet formulas. bImmunocompromised status includes hematologic malignancy, solid tumor, solid organ transplantation, liver cirrhosis Child B or C, or autoimmune diseases requiring long-term immunosuppressive therapy
  2. *p < 0.05. (in the comparisons between survivors and non-survivors)